Fractyl – First AAV Trial in Type 2 Diabetes

Summary Fractyl Health has received authorization in the Netherlands to initiate the first-in-human clinical trial of RJVA-001, an AAV-based gene therapy for type 2 diabetes, marking the first clinical-stage gene therapy program targeting the disease. What Happened The Dutch regulatory authority authorized Fractyl to begin…